Protara Therapeutics Q2 2025 Earnings Results & Report

Protara Therapeutics EPS Results

• Actual EPS: -$0.35
• Consensus EPS: -$0.43
• Beat/Miss: Beat by +$0.08
• One Year Ago EPS: N/A
• EPS Beat Rate: 5 of last 8 quarters

Protara Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Protara Therapeutics (NASDAQ:TARA) is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and rare diseases. The company’s work centers on investigational treatments intended to address conditions with significant unmet medical needs.

Protara’s lead product candidate is TARA-002, an investigational cell-based therapy derived from OK-432, a preparation based on a strain of Streptococcus pyogenes. The company is developing TARA-002 for non-muscle-invasive bladder cancer, a form of bladder cancer that has not invaded the bladder muscle, and for lymphatic malformations, rare abnormalities of the lymphatic system.

Protara conducts its research and clinical development activities primarily in the United States. Its product candidates remain investigational and have not been approved for commercial use by the U.S. Food and Drug Administration or other regulatory authorities.